ARQT

Arcutis Biotherapeutics, Inc. (ARQT) - Q1 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025. Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on dermatological diseases. Its primary commercial products are the ZORYVE® (roflumilast) franchise, including cream 0.3% for plaque psoriasis, foam 0.3% for seborrheic dermatitis, and cream 0.15% for atopic dermatitis. The company operates as a single reportable segment.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 33% year-over-year, driven by a 196% surge in product revenue. ZORYVE foam revenue grew 362% due to U.S. and Canadian launches, while ZORYVE cream 0.3% grew 56%. The new ZORYVE cream 0.15% contributed $10.2 million in its first full quarter of U.S. sales.
• Other Revenue Decline: Other revenue dropped significantly from $28.0 million to $2.0 million. The prior year included a $25.0 million upfront payment from the Sato License Agreement, which did not recur in Q1 2025.
• Cost of Sales Increase: Cost of sales rose to $8.8 million (from $3.3 million), primarily due to a $10.0 million cumulative catch-up amortization expense related to an AstraZeneca sales milestone achieved in Q1 2025.
• Expense Management: R&D expenses decreased 24% to $17.5 million due to the completion of Phase 3 studies for roflumilast cream in atopic dermatitis. SG&A expenses increased 17% to $64.0 million, driven by commercialization efforts and a new co-promotion agreement with Kowa Pharmaceuticals.
• Interest Expense Reduction: Interest expense fell to $3.0 million (from $7.5 million) following a $100 million principal paydown in October 2024 and lower interest rates.

Outlook, Risks, and Unusual Items

• Liquidity: Management believes existing capital resources ($198.7 million in cash/securities plus $100 million available under the Loan Agreement) are sufficient for at least 12 months. The company expects to continue incurring operating losses.
• Debt Structure: The company has $100 million outstanding under its Loan Agreement with SLR Investment Corp. The agreement includes a financial covenant requiring minimum net product revenue of 75% of projected annual plans. The company was in compliance as of March 31, 2025.
• Regulatory Milestones:
  • ZORYVE Foam: FDA PDUFA date for scalp and body psoriasis label expansion is May 22, 2025.
  • ZORYVE Cream 0.05%: FDA PDUFA date for pediatric atopic dermatitis (ages 2-5) is October 2025.
• Legal Proceedings: A patent infringement lawsuit against Padagis regarding a generic ZORYVE cream was stayed by the court on April 3, 2025. The 30-month stay on FDA approval of the generic is extended for the duration of the case stay. Oppositions to European patents by Teva are ongoing.
• Unusual Items: The $10.0 million AstraZeneca milestone payment was recorded as a cumulative catch-up adjustment to intangible assets, impacting Q1 cost of sales significantly.

Investor Verification Checklist

• Debt Covenants: Verify continued compliance with the 75% revenue covenant under the SLR Loan Agreement, especially given the high interest rate (10.27% as of March 31, 2025).
• Regulatory Timelines: Monitor the May 2025 PDUFA date for ZORYVE foam psoriasis expansion and the October 2025 date for pediatric atopic dermatitis approval.
• Generic Competition: Track the status of the Padagis litigation stay and the potential impact on ZORYVE cream 0.3% exclusivity.
• Commercial Execution: Assess the performance of the new Kowa co-promotion agreement in primary care and pediatrics.
• Cash Burn: Monitor the trajectory of operating cash burn ($30.4 million in Q1) against the $198.7 million liquidity position.